ADJUVANT PUBLICATIONS & ABSTRACTS
Adjuvant data
Evidence / Adjuvant
Characterisation of Multifocal Breast Cancer Using the 70-gene Signature in Clinical Low-Risk Patients Enrolled in the EORTC 10041/BIG 03-04 MINDACT Trial.
PUBLICATION: European Journal of Cancer. July 2017, Volume 79, Pages 98–105. AUTHORS: K.C. Aalders, A. Kuijerb, M.E. Straver, L. Slaets, S. Litiere, G. Viale, L.J. van't Veer, A.M. Glas, M. Delorenzi, T. van Dalen, K. Tryfonidis, M.J. Piccart, F. Cardoso, E.J. Rutgers on behalf of the TRANSBIG Consortium and the Read More
A Breast Cancer Gene Signature for Indolent Disease
PUBLICATION: Breast Cancer Res Treat. 2017 Oct;117(3):483-95. doi: 10.1007/s10549-008-0191-2. Epub 2008 Sep 26. AUTHORS: Leonie J.M.J. Delahaye, Caroline A. Drukker, Christa Dreezen, Anke Witteveen, Bob Chan, Mireille Snel, Inès J. Beumer, Rene Bernards, M. William Audeh, Laura J. van’t Veer, Annuska M. Glas SUMMARY: An Ultralow Risk development paper. In Read More
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
PUBLICATION: N Engl J Med 2016; 375:717-729; DOI: 10.1056/NEJMoa1602253. AUTHORS: Fatima Cardoso, M.D., Laura J. van’t Veer, Ph.D., Jan Bogaerts, Ph.D., Leen Slaets, Ph.D., Giuseppe Viale, M.D., Suzette Delaloge, M.D., Jean-Yves Pierga, M.D., Ph.D., Etienne Brain, M.D., Ph.D., Sylvain Causeret, M.D., Mauro DeLorenzi, Ph.D., Annuska M. Glas, Ph.D., Vassilis Golfinopoulos, Read More
MINDACT Supplementary Appendix NEJM 2016
SUPPLEMENTARY APPENDIX: This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Cardoso F., van’t Veer L.J., Bogaerts J., et al. 70-Gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med 2016;375:717-29. DOI: 10.1056/NEJMoa1602253. Read Read More
Gene Expression Profiling to Predict the Risk of Locoregional Recurrence in Breast Cancer: A Pooled Analysis
PUBLICATION: Breast Cancer Res Treat (2014) 148: 599. https://doi.org/10.1007/s10549-014-3188-z. AUTHORS: C.A. Drukker, S.G. Elias, M.V. Nijenhuis, J. Wesseling, H. Bartelink, P. Elkhuizen, B. Fowble, P.W. Whitworth, R.R. Patel, F.A. de Snoo, L.J. van ’t Veer, P.D. Beitsch, E.J. Th. Rutgers SUMMARY: After a median follow-up of 8.96 years with 87 Read More
The Multigene Signature MammaPrint Impacts on Multidisciplinary Team Decisions in ER+, HER2− Early Breast Cancer
PUBLICATION: British Journal of Cancer, volume 111, pages 837–842 (26 August 2014). AUTHORS: R. Exner, Z. Bago-Horvath, R. Bartsch, M. Mittlboeck, V.P. Retèl, F. Fitzal, M. Rudas, C. Singer, G. Pfeiler, M. Gnant, R. Jakesz, P. Dubsky SUMMARY: According to MammaPrint (MP), 76% were low risk. In over a third Read More
European Inter-Institutional Impact Study of MammaPrint
PUBLICATION: The Breast August 2014, Volume 23, Issue 4, Pages 423–428 AUTHORS: P.G. Cusumano, D. Generali, E. Ciruelos, L. Manso, I. Ghanem, E. Lifrange, G. Jerusalem, J. Klaase, F. de Snoo, L. Stork-Sloots, L. Dekker-Vroling, M. Lutke Holzik SUMMARY: Using MammaPrint, chemotherapy treatment advice for ER+/HER2- breast cancer patients was Read More
